[Thiopurine-methyltransferase genotyping prior to thiopurine therapy]
Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Oubiña M
Record ID 32014000245
Spanish
Authors' objectives:
To assess the evidence available on the efficacy, safety, and other coverage policy related aspects on the use of TPMT enzyme allele genotyping prior to thiopurine therapy.
Authors' recommendations:
The quality of the evidence found is poor. At present, there are no studies showing that this technology decreases the rate of adverse events, hospitalizations or mortality. There is conflict about recommending this technology, taking into account that each source considers the efficacy of genotyping versus standard approach to prevent myelosuppression in different pathologies and with varying prognoses.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.iecs.org.ar/home-ets/?cod_publicacion=1565&familia=5&origen_publicacion=buscador
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Genotyping Techniques
- Methyltransferases
- Phenotype
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.